147 related articles for article (PubMed ID: 33174084)
1. The role of circulating tumor cells and K-ras mutations in patients with locally advanced rectal cancer: a prospective study.
Bahnassy AA; Abdel-Azim YA; Ezzat S; Abdellateif MS; Zekri AN; Mohanad M; Salama A; Khaled H
Mol Biol Rep; 2020 Dec; 47(12):9645-9657. PubMed ID: 33174084
[TBL] [Abstract][Full Text] [Related]
2. Molecular and Dynamic Evaluation of Proteins Related to Resistance to Neoadjuvant Treatment with Chemoradiotherapy in Circulating Tumor Cells of Patients with Locally Advanced Rectal Cancer.
Silva VSE; Abdallah EA; Flores BCT; Braun AC; Costa DJF; Ruano APC; Gasparini VA; Silva MLG; Mendes GG; Claro LCL; Calsavara VF; Aguiar Junior S; de Mello CAL; Chinen LTD
Cells; 2021 Jun; 10(6):. PubMed ID: 34207124
[TBL] [Abstract][Full Text] [Related]
3. Detection of circulating tumor cells in patients with locally advanced rectal cancer undergoing neoadjuvant therapy followed by curative surgery.
Magni E; Botteri E; Ravenda PS; Cassatella MC; Bertani E; Chiappa A; Luca F; Zorzino L; Bianchi PP; Adamoli L; Sandri MT; Zampino MG
Int J Colorectal Dis; 2014 Sep; 29(9):1053-9. PubMed ID: 25008360
[TBL] [Abstract][Full Text] [Related]
4. Molecular and Kinetic Analyses of Circulating Tumor Cells as Predictive Markers of Treatment Response in Locally Advanced Rectal Cancer Patients.
Troncarelli Flores BC; Souza E Silva V; Ali Abdallah E; Mello CAL; Gobo Silva ML; Gomes Mendes G; Camila Braun A; Aguiar Junior S; Thomé Domingos Chinen L
Cells; 2019 Jun; 8(7):. PubMed ID: 31247977
[TBL] [Abstract][Full Text] [Related]
5. KRAS mutations by digital PCR in circulating tumor cells isolated from the mesenteric vein are associated with residual disease and overall survival in resected colorectal cancer patients.
Li Y; Monzo M; Moreno I; Martinez-Rodenas F; Hernandez R; Castellano JJ; Canals J; Han B; Muñoz C; Navarro A
Int J Colorectal Dis; 2020 May; 35(5):805-813. PubMed ID: 32088737
[TBL] [Abstract][Full Text] [Related]
6. Impact of RAS/BRAF mutation status in locally advanced rectal cancer treated with preoperative chemotherapy.
Oshiro T; Uehara K; Aiba T; Mukai T; Ebata T; Nagino M
Int J Clin Oncol; 2018 Aug; 23(4):681-688. PubMed ID: 29478127
[TBL] [Abstract][Full Text] [Related]
7. Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer.
Chen Z; Duldulao MP; Li W; Lee W; Kim J; Garcia-Aguilar J
J Am Coll Surg; 2011 Jun; 212(6):1008-1017.e1. PubMed ID: 21458303
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of circulating tumor cells (CTCs) in Egyptian non-metastatic colorectal cancer patients: A comparative study for four different techniques of detection (Flowcytometry, CellSearch, Quantitative Real-time PCR and Cytomorphology).
Bahnassy AA; Salem SE; Mohanad M; Abulezz NZ; Abdellateif MS; Hussein M; Zekri CAN; Zekri AN; Allahloubi NMA
Exp Mol Pathol; 2019 Feb; 106():90-101. PubMed ID: 30578762
[TBL] [Abstract][Full Text] [Related]
9. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
Banys-Paluchowski M; Fehm T; Janni W; Aktas B; Fasching PA; Kasimir-Bauer S; Milde-Langosch K; Pantel K; Rack B; Riethdorf S; Solomayer EF; Witzel I; Müller V
BMC Cancer; 2018 May; 18(1):541. PubMed ID: 29739347
[TBL] [Abstract][Full Text] [Related]
11. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of tumour regression grade after neoadjuvant chemoradiotherapy for a cohort of patients with locally advanced rectal cancer: an 8-year retrospective single-institutional study.
Xu L; Cai S; Xiao T; Chen Y; Qiu H; Wu B; Lin G; Sun X; Lu J; Zhou W; Xiao Y
Colorectal Dis; 2017 Jul; 19(7):O263-O271. PubMed ID: 28603932
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Lymph Node Ratio in Locally Advanced Rectal Cancer Patients After Preoperative Chemoradiotherapy Followed by Total Mesorectal Excision.
Zuo ZG; Zhang XF; Wang H; Liu QZ; Ye XZ; Xu C; Wu XB; Cai JH; Zhou ZH; Li JL; Song HY; Luo ZQ; Li P; Ni SC; Jiang L
Medicine (Baltimore); 2016 Mar; 95(9):e2988. PubMed ID: 26945418
[TBL] [Abstract][Full Text] [Related]
14. Metastasis risk stratification and response prediction through dynamic viable circulating tumor cell counts for rectal cancer in a neoadjuvant setting.
Liu WY; Zhang W; Tang Y; Chen SL; Li N; Lei JQ; Shi JM; Wang SL; Li YX; Zhang KT; Jin J
Cancer Med; 2023 May; 12(10):11438-11450. PubMed ID: 37014817
[TBL] [Abstract][Full Text] [Related]
15. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
[TBL] [Abstract][Full Text] [Related]
16. Joint quantitative measurement of hTERT mRNA in both peripheral blood and circulating tumor cells of patients with nasopharyngeal carcinoma and its clinical significance.
Fu X; Shen C; Wang H; Chen F; Li G; Wen Z
BMC Cancer; 2017 Jul; 17(1):479. PubMed ID: 28693532
[TBL] [Abstract][Full Text] [Related]
17. Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer.
Zhou P; Goffredo P; Ginader T; Thompson D; Hrabe J; Gribovskaja-Rupp I; Kapadia M; Hassan I
J Surg Oncol; 2021 Jan; 123(1):278-285. PubMed ID: 33022750
[TBL] [Abstract][Full Text] [Related]
18. Oncogene mutation profile predicts tumor regression and survival in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy and radical surgery.
Peng J; Lin J; Qiu M; Zhao Y; Deng Y; Shao J; Ding P; Zhang H; Wan D; Lu Z; Pan Z
Tumour Biol; 2017 Jul; 39(7):1010428317709638. PubMed ID: 28671043
[TBL] [Abstract][Full Text] [Related]
19. Practical utility of circulating tumour cells as biomarkers in cancer chemotherapy for advanced colorectal cancer.
Otsuka K; Imai H; Soeda H; Komine K; Ishioka C; Shibata H
Anticancer Res; 2013 Feb; 33(2):625-9. PubMed ID: 23393358
[TBL] [Abstract][Full Text] [Related]
20. Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer.
Hammarström K; Nunes L; Mathot L; Mezheyeuski A; Lundin E; Korsavidou Hult N; Imam I; Osterlund E; Sjöblom T; Glimelius B
Int J Cancer; 2024 Jul; 155(1):40-53. PubMed ID: 38376070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
